The microbiome represents a paradigm shift that affects every aspect of biomedicine: our gut bacteria control health, disease and drug response throughout the body, and can themselves be a novel type of medicine. The microbiome therefore has the potential to be a major new therapeutic modality.

Microbiotica was founded by Dr Trevor Lawley, Dr Mike Romanos and Prof Gordon Dougan FRS in December 2016 to exploit fundamental advances made at the Sanger Institute to address barriers to the translation of the microbiome.

A central premise has been that a more rigorous and comprehensive analysis and understanding of the role of the gut bacteria in patients is required to drive the development of Live Bacterial Therapeutics and microbiome-based biomarkers of disease and drug response.

Microbiotica has built a powerful team comprising all the disciplines to undertake this work from analysis of patient data through to clinical trials, and has a portfolio of programs in IBD, Immuno-oncology and Gut Epithelial Repair.

The company is supported by a highly expert network of scientific advisers. Microbiotica has received investment and support from leading investors British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners and Tencent.